Bone drug extends life in fast-aging mice

RANKL is a protein that plays a central role in bone breakdown. It drives the activity of osteoclasts (cells that break down bone tissue) via the receptor RANK. In healthy bone renewal, osteoclasts and osteoblasts (cells that build bone) stay in balance. With aging, that balance shifts toward breakdown, leading to osteoporosis. Drugs that inhibit RANKL are already used to slow this process.

The researchers used mice with Hutchinson-Gilford progeria, a rare condition in which people display signs resembling accelerated aging from an early age. In these mice, RANKL was suppressed in two ways: via a genetic modification in bone-forming cells, and via a neutralising antibody (a protein that blocks RANKL). Both approaches led to improved bone, less muscle tissue damage, and longer lifespan.

Muscles benefit too

Notably, the mice also showed better grip strength and greater endurance. This points to RANKL having an influence on muscle aging independently of its bone effects. This fits with earlier research suggesting RANKL plays a broader role in the aging process than simply regulating bone tissue.

Whether these findings apply to normally aging mice, or to humans, has not yet been studied. Progeroid mice age faster than normal, which makes the model useful but also limits its direct applicability. The authors are cautious and call for follow-up studies in conventional aging models.

Link to existing treatments

From a longevity science standpoint, it is notable that RANKL inhibition overlaps with existing drug classes already used in humans, including bisphosphonates (agents that suppress bone breakdown via a different mechanism). Earlier human research has associated bisphosphonate use with longer survival. Whether this relates to bone protection, a direct effect on aging cells, or both, remains an open question.

Read the original article